Trial Halted for Bleeding Reduction With Abelacimab in AF Trial Halted for Bleeding Reduction With Abelacimab in AF

The phase 2 AZALEA-TIMI 71 trial in AF shows"an overwhelming reduction" in major and clinically relevant nonmajor bleeding with investigational Factor XI inhibitor abelacimab vs rivaroxaban.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Cardiology News Source Type: news